Addition of a CSF-1R inhibitor potentiates and overcomes resistance to checkpoint inhibitors in other solid tumour models [215,216], suggesting that combination of a checkpoint inhibitor with a CSF-1R inhibitor could have potential in osteosarcoma therapy. The gene discussed is CSF1R; the disease is osteosarcoma.